Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Nuwellis Inc NUWE

Healthcare Medical Devices

Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms... see more

Add To Watchlist

Recent & Breaking News (NDAQ:NUWE)

Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

GlobeNewswire February 7, 2023

Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results

GlobeNewswire January 9, 2023

Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer

GlobeNewswire January 5, 2023

Nuwellis, Inc. Announces Passage of Warrant Proposal

GlobeNewswire January 4, 2023

Nuwellis, Inc. Announces Compliance With Nasdaq Listing Requirements

GlobeNewswire December 27, 2022

Nuwellis Announces Data Supporting Lower Heart Failure Hospitalizations and Readmissions With Aquadex

GlobeNewswire December 13, 2022

Nuwellis, Inc. Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

GlobeNewswire December 8, 2022

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

GlobeNewswire November 30, 2022

Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 18, 2022

Nuwellis, Inc. Reports Third Quarter 2022 Financial Results

GlobeNewswire November 8, 2022

Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates

GlobeNewswire November 3, 2022

Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022

GlobeNewswire October 19, 2022

Nuwellis Announces Appointment of Chief Financial Officer

GlobeNewswire October 19, 2022

Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

GlobeNewswire October 18, 2022

Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering

GlobeNewswire October 14, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

GlobeNewswire October 3, 2022

Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

GlobeNewswire September 27, 2022

Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

GlobeNewswire August 31, 2022

U.S. Patent and Trademark Office Awards Nuwellis Patent for Innovative Pediatric Technology

GlobeNewswire August 25, 2022

Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 19, 2022